ArticleDigestive diseases and sciences2015
Clinical significance of C-reactive protein levels in predicting responsiveness to iron therapy in patients with inflammatory bowel disease and iron deficiency anemia.
Article in Digestive diseases and sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02760940 (Anemia Treatment in Inflammatory Bowel Disease), which is not on this map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Anemia Treatment in Inflammatory Bowel Disease: Predictive Factors of Response to Oral Iron Treatment
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Interventions for treating iron deficiency anaemia in inflammatory bowel disease.The Cochrane database of systematic reviews · 2021Pooled it
- Trial
- Improved Hemoglobin Response with Ferric Carboxymaltose in Patients with Gastrointestinal-Related Iron-Deficiency Anemia Versus Oral Iron.Digestive diseases and sciences · 2018Trial
- Oral Iron Treatment Response and Predictors in Anaemic Adolescents and Adults with IBD: A Prospective Controlled Open-Label Trial.Journal of Crohn's & colitis · 2017Trial
- Impact of inflammatory status on intestinal iron absorption in older hospitalized patients.European journal of clinical nutrition · 2025Article
- C-Reactive Protein and Long-Term Prognosis in Adult Patients with Congenital Heart Disease.Journal of clinical medicine · 2024Article
- The Role of Vitamins in Spinal Cord Injury: Mechanisms and Benefits.Oxidative medicine and cellular longevity · 2024Review
- Sarcopenia and Anemia in Elderly Koreans: A Nationwide Population-Based Study.Healthcare (Basel, Switzerland) · 2023Article
- Review
- Decreased serum iron concentration and total iron binding capacity are associated with serious Crohn's disease.Scientific reports · 2022Article
- Neutrophil to Lymphocyte and Platelet to Lymphocyte Ratios in Normal Tension Glaucoma.Medical hypothesis, discovery & innovation ophthalmology journal · 2019Article
- Established and Emerging Concepts to Treat Imbalances of Iron Homeostasis in Inflammatory Diseases.Pharmaceuticals (Basel, Switzerland) · 2018Review
- Impact of Inflammation on Ferritin, Hepcidin and the Management of Iron Deficiency Anemia in Chronic Kidney Disease.Nutrients · 2018Review
- Review
- Hepcidin as a potential predictor for preoperative anemia treatment with intravenous iron-A retrospective pilot study.PloS one · 2018Article
- Regulation of platelet count by erythropoiesis-stimulating agents - iron axis in hemodialysis patients.International journal of nephrology and renovascular disease · 2016Article
- The Influence of Anti-tumor Necrosis Factor Agents on Hemoglobin Levels of Patients with Inflammatory Bowel Disease.Inflammatory bowel diseases · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIron deficiency anemia (IDA) is a common complication of inflammatory bowel disease (IBD). In clinical practice, many patients receive initial treatment with iron tablets although intravenous (i.v.) iron supplementation is often preferable.
aimThis study investigated whether systemic inflammation at initiation of treatment (assessed by C-reactive protein [CRP] and interleukin-6 [IL-6] measurements) predicts response to iron therapy.
methodsData from a previously published phase III trial were retrospectively analyzed after stratification of patients according to baseline CRP (> 4 vs. ≤ 4 mg/L) and IL-6 (> 6 vs. ≤ 6 pg/mL) levels. The study population consisted of patients with Crohn's disease or ulcerative colitis and IDA (Hb ≤ 110 g/L and TSAT < 20 % or serum ferritin < 100 ng/mL), randomized to either oral (ferrous sulfate) or i.v. iron (ferric carboxymaltose).
resultsA total of 196 patients were evaluated (oral iron: n = 60; i.v. iron: n = 136). Baseline CRP and IL-6 levels were independent of patients' initial Hb levels and iron status (serum ferritin and TSAT; all p > 0.05). Among iron tablet-treated patients, Hb increase was significantly smaller in the high- versus low-CRP subgroup (1.1 vs. 2.0, 2.3 vs. 3.1, and 3.0 vs. 4.0 g/dL at weeks 2, 4, and 8, respectively; all p < 0.05). Differences were less pronounced with stratification according to baseline IL-6. Response to i.v. iron was mainly independent of inflammation.
conclusionsPatients with high baseline CRP achieved a lower Hb response with oral iron therapy. Our results suggest that CRP may be useful to identify IBD patients who can benefit from first-line treatment with i.v. iron to improve their IDA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.